Learn more about our programs

Navigating Treatment with BTK Inhibitors

Now Available On Demand


Produced in collaboration with CLL Society and The Leukemia & Lymphoma Society.
Support for this patient education program was provided by AstraZeneca; Pharmacyclics LLC, an AbbVie Company; and Janssen Biotech, Inc.

A diagnosis of chronic lymphocytic leukemia (CLL) can be a challenging experience for patients, families, and caregivers. Learning about the condition and the available treatment, resource, and support options can help patients successfully navigate the disease.

“Improving CLL Point-of-Care Decisions Utilizing BTK Inhibitors” is an education series consisting of 2 modules and is designed to help patients and caregivers understand the available treatment options for CLL across the continuum of care, learn about the details of BTK-inhibitor treatments, and confidently talk with their doctors and other clinicians to align their goals and priorities for care. View the modules in any order and return at any time.

In Module 1, “Navigating Treatment with BTK Inhibitors,” expert hematology/oncology clinicians and a CLL patient discuss challenges associated with BTK-inhibitor use in the treatment of CLL. Panelists explore the latest findings on long-term efficacy, side-effect management, and adopting healthy lifestyles to improve outcomes.

You’ll learn about:

  • Challenges managing treatment with BTK inhibitors
  • Newly diagnosed and relapsed/refractory settings
  • Long-term efficacy of BTK inhibitors
  • Adverse-event management
  • Healthy lifestyles to improve outcomes

Module 2, “Aligning Patient and Provider Goals,” is now available. Expert clinicians answer patient/caregiver-submitted questions about CLL, treatments, side effects and working with the health care team.

Register to watch on demand




Matthew S. Davids, MD, MMSC

Associate Professor of Medicine, Harvard Medical School

Matthew S. Davids, MD, MMSC, is an attending physician in the Lymphoma Program of the Division of Hematologic Malignancies and associate director of the CLL Center at Dana-Farber Cancer Institute, as well as an associate professor of medicine at Harvard Medical School in Boston. He has an active translational research program in chronic lymphocytic leukemia (CLL), studying Bcl-2 biology in his laboratory and leading clinical trials to evaluate a variety of novel therapeutic strategies in patients with CLL and other hematologic malignancies. Dr Davids received his medical degree from Yale School of Medicine in New Haven, Connecticut.

Susan O'Brien, MD

Professor, Division of Hematology/Oncology, University of California, Irvine School of Medicine Associate Director for Clinical Sciences Chao Family Comprehensive Cancer Center

Elizabeth Dechen

Patient Advocate

Brad Adams

Interview Participant




  • CLL Society logo
  • LLS